Literature DB >> 11458402

Common femoral artery anatomy is influenced by demographics and comorbidity: implications for cardiac and peripheral invasive studies.

G Schnyder1, N Sawhney, B Whisenant, S Tsimikas, Z G Turi.   

Abstract

We assessed the angiographic size of the common femoral artery (CFA) and the influence of demographics and comorbidites. In addition, the location of the CFA bifurcation and the site of femoral puncture were also assessed. Consecutive CFA angiograms (n = 200) were prospectively analyzed. CFA diameter was 6.9 +/- 1.4 mm and length 43.3 +/- 16.2 mm. By multivariate analysis, only diabetes (P < 0.001), female gender (P < 0.0005), and small body surface area (P < 0.01) predicted small vessel size. Vessel length correlated with patient height (P < 0.0005). CFA bifurcation occurred at or below the femoral head center in 98.5%. The femoral puncture was into a vessel other than the CFA in 13%, and 54% of punctures were in a less than ideal anatomical location. In conclusion, the CFA is a relatively small diameter vessel, particularly in diabetics and women. Puncture above the femoral head center and below the superior margin of the acetabulum accurately predicts an ideal puncture site. Thus, routine fluoroscopic guidance should be considered. Cathet Cardiovasc Intervent 2001;53:289-295. Copyright Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11458402     DOI: 10.1002/ccd.1169

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  21 in total

Review 1.  Echocardiographic guidance for diagnostic and therapeutic percutaneous procedures.

Authors:  Cam Tu Nguyen; Eunice Lee; Huai Luo; Robert J Siegel
Journal:  Cardiovasc Diagn Ther       Date:  2011-12

Review 2.  Achieving safe femoral arterial access.

Authors:  Michael S Lee; Jeremy Kong
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 3.  Access and hemostasis: femoral and popliteal approaches and closure devices-why, what, when, and how?

Authors:  Iacopo Barbetta; Jos C van den Berg
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

4.  Peri-procedural complications in women: an alarming and consistent trend.

Authors:  Libo Wang; Kimberly A Selzman; Rashmee U Shah
Journal:  Eur Heart J       Date:  2019-09-21       Impact factor: 29.983

Review 5.  Toward microendoscopy-inspired cardiac optogenetics in vivo: technical overview and perspective.

Authors:  Aleksandra Klimas; Emilia Entcheva
Journal:  J Biomed Opt       Date:  2014-08       Impact factor: 3.170

6.  The effect of gender on outcomes of aortoiliac artery interventions for claudication.

Authors:  Venkataramu N Krishnamurthy; Muhammad Naeem; Timothy P Murphy; Joselyn Cerezo; Paul Gaither Jordan; Suzanne H Goldberg; Abby G Ershow; Alan T Hirsch; Niki Oldenburg; Donald E Cutlip
Journal:  Clin Imaging       Date:  2015-09-04       Impact factor: 1.605

7.  Bleeding avoidance strategies. Consensus and controversy.

Authors:  Harold L Dauerman; Sunil V Rao; Frederic S Resnic; Robert J Applegate
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

8.  Vascular Access and Chronic Total Occlusion Angioplasty.

Authors:  David Smith; Ahmed Hailan; Alexander Chase
Journal:  Interv Cardiol       Date:  2015-05

9.  Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation.

Authors:  Timir S Baman; Krit Jongnarangsin; Aman Chugh; Arisara Suwanagool; Aurelie Guiot; Arin Madenci; Spencer Walsh; Karl J Ilg; Sanjaya K Gupta; Rakesh Latchamsetty; Suveer Bagwe; James D Myles; Thomas Crawford; Eric Good; Frank Bogun; Frank Pelosi; Fred Morady; Hakan Oral
Journal:  J Cardiovasc Electrophysiol       Date:  2011-01-15

10.  Gender related differences in predictors of vascular complications: role of vessel size and BMI.

Authors:  Bina Ahmed; Stefan Lischke; Mike De Sarno; Leigh Ann Holterman; Faye Straight; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.